Study of High Potential for Addiction Group 1 Psychotropic Drugs Used in Science
Abstract
Background. Research on high-potential addiction psychotropic drugs from Group 1 is an essential undertaking in the fields of pharmacology and mental health treatment, requiring an extensive introduction to provide context and delineate its importance and breadth.
Purpose. This study offers a comprehensive examination of Group 1 psychotropic drugs, emphasizing their pharmacological characteristics, addictive tendencies, and regulatory implications
Method. Drawing upon data extracted from Indonesian Ministry of Health Regulation No. 10 of 2022, the research compiles and delineates the psychotropic drugs falling under Group 1 classification.
Results. Drugs name as Deskloro ketamin, 2F- Deskloro ketamin, Flubroma zolam, Flualpra zolam, Klonazolam are identified, each presenting distinct pharmacological effects and addiction potentials. The study highlights the imperative for stringent regulatory measures owing to the pronounced likelihood of abuse and adverse consequences associated with these substances. Regulatory frameworks must remain dynamic to effectively address emerging challenges and evolving patterns of drug usage.
Conclusion. This research significantly contributes to the comprehension of psychotropic drugs and informs strategies aimed at ensuring their judicious and safe utilization.
Full text article
References
Aditama, A. S. (2015). Penggabungan Psikotropika Golongan I Dan Golongan Ii Ke Dalam Narkotika Golongan I Dalam Undang-Undang Nomor 35 Tahun 2009 (Doctoral dissertation, UNIVERSITAS AIRLANGGA).
Alifia, U. (2020). Apa Itu Narkotika dan Napza?. Alprin.
Ardianto, N., Saristiana, Y., Septiarini, A. D., Permatasari, Y. D., Hasriyani, H., Prasetyawan, F., ... & Wahab, C. S. (2024). Forensic Pharmacy Analysis of Illegal Drug Trade: A Case Study of Confiscated Goods by BPOM Semarang in 2018 within the Context of Business and Economics. International Journal of Asian Business and Development, 1(1).
Bonnet, U., Specka, M., Soyka, M., Alberti, T., Bender, S., Grigoleit, T., ... & Scherbaum, N. (2020). Ranking the harm of psychoactive drugs including prescription analgesics to users and others–a perspective of german addiction medicine experts. Frontiers in psychiatry, 11, 592199.
Grüsser, S. M., Thalemann, C. N., Platz, W., Gölz, J., & Partecke, G. (2006). A new approach to preventing relapse in opiate addicts: a psychometric evaluation. Biological psychology, 71(3), 231-235.
Hariyanto, B. P. (2018). Pencegahan dan Pemberantasan peredaran narkoba di Indonesia. Jurnal Daulat Hukum, 1(1).
Kuhn, J., Bührle, C. P., Lenartz, D., & Sturm, V. (2013). Deep brain stimulation in addiction due to psychoactive substance use. Handbook of clinical neurology, 116, 259-269.
Liechti, M. E. (2015). Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling. Swiss medical weekly, 145, w14043.
Luki?, V., Mici?, R., Arsi?, B., Nedovi?, B., & Radosavljevi?, Ž. (2021). Overview of the major classes of new psychoactive substances, psychoactive effects, analytical determination and conformational analysis of selected illegal drugs. Open Chemistry, 19(1), 60-106.
Milkman, H., & Sunderwirth, S. (1982). Addictive processes. Journal of Psychoactive Drugs, 14(3), 177-192.
Müller, C. P. (2017). Non addictive drug use: the way forward. The SAGE Handbook of Drugs & Alcohol Studies–Biological Approaches, 2, 411-34.
Müller, C. P., & Schumann, G. (2011). Drugs as instruments: a new framework for non-addictive psychoactive drug use. Behavioral and Brain Sciences, 34(6), 293-310.
Nicholi Jr, A. M. (1983). The nontherapeutic use of psychoactive drugs: A modern epidemic. New England Journal of Medicine, 308(16), 925-933.
Nicholi Jr, A. M. (1983). The nontherapeutic use of psychoactive drugs: A modern epidemic. New England Journal of Medicine, 308(16), 925-933.
O’Brien, C. P. (2005). Anticraving medications for relapse prevention: a possible new class of psychoactive medications. American Journal of Psychiatry, 162(8), 1423-1431.
Prasetyawan, F., Wahdi, A., Saristiana, Y., & Puspitasari, D. R. (2024). Psikofarmaka Medications in Influencing Mental Activity and Behavior Through Selective Action on the Central Nervous System: Article Study. International Journal of Asian Education and Psychology, 1(2).
Rounsaville, B. J., Weissman, M. M., Kleber, H., & Wilber, C. (1982). Heterogeneity of psychiatric diagnosis in treated opiate addicts. Archives of general psychiatry, 39(2), 161-166.
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015). Novel psychoactive substances of interest for psychiatry. World Psychiatry, 14(1), 15-26.
Tettey, J. N., Crean, C., Ifeagwu, S. C., & Raithelhuber, M. (2018). Emergence, diversity, and control of new psychoactive substances: a global perspective. New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology, 51-67.
Varì, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2019). New psychoactive substances—synthetic stimulants. Wiley Interdisciplinary Reviews: Forensic Science, 1(2), e1197.
Vetulani, J. (2001). Drug addiction. Part 1. Psychoactive substances in the past and presence. Polish journal of pharmacology, 53(3), 201-214.
Wiedermann, W., Niggli, J., & Frick, U. (2014). The Lemming-effect: Harm perception of psychotropic substances among music festival visitors. Health, Risk & Society, 16(4), 323-338.
Authors
Copyright (c) 2024 Yuneka Saristiana, Fendy Prasetyawan, Ratna Mildawati, Chandra Arifin, Faisal Akhmal Muslikh, Abd Rofiq, Widhi Astutik
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.